SCHEDULE: Vanguard Group Amends Denali Therapeutics Stake to Zero
Beneficial Ownership Amendment
The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Denali Therapeutics Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 6 to its Schedule 13G for Denali Therapeutics Inc. common stock.
- The filing reports 0 beneficial ownership of Denali Therapeutics Inc. common stock, representing 0% of the class.
- This change is attributed to an internal realignment at The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing. It reflects an internal organizational change at The Vanguard Group regarding how its beneficial ownership is reported, rather than a change in investment thesis for Denali Therapeutics.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine for large institutional investors like The Vanguard Group. This specific amendment reflects an internal organizational change within Vanguard regarding how its various entities report their holdings, rather than a strategic investment decision regarding Denali Therapeutics. It indicates a shift to disaggregated reporting by subsidiaries, not necessarily a divestment from the underlying company by Vanguard's broader investment complex.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders of Denali Therapeutics Inc. may observe the change in reporting by a major institutional investor, but it does not inherently imply a change in investment strategy by Vanguard's overall funds. It is primarily an internal reporting adjustment for The Vanguard Group.
Key Dates
| Date | Description |
|---|---|
| 01/12/2026 | The Vanguard Group, Inc. underwent an internal realignment. |
| 03/13/2026 | Date of the event which required the filing of this statement (change in beneficial ownership reporting). |
| 03/26/2026 | Date the Schedule 13G Amendment No. 6 was signed by The Vanguard Group. |
Keywords
Denali Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional investor, common stock, SEC filing, investment adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.